AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23283645 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured isometric exercise program
Number of subjects: 50
Study 23283645 — intervention group
Group type: COMPARATOR
Intervention: Simple hand exercise (control group)
Number of subjects: 50
Study 21645018 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 313
Study 19916311 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-ozone baths (20 minutes, ozone concentration 8-10 mg/l, temperature 36 degrees C, 10 daily procedures)
Number of subjects: 160
Study 19916311 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 patients without operational treatment)
Number of subjects: 160
Study 17137887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully vaccinated (FV)
Number of subjects: 5193
Study 17137887 — intervention group
Group type: COMPARATOR
Intervention: Partially vaccinated (PV)
Number of subjects: 5193
Study 11823663 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 degrees C)
Number of subjects: 12
Study 10401508 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 152
Study 10401508 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Vocational Rehabilitation (EVR)
Number of subjects: 152
Study 7580021 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of hMG (75 IU/day) in desensitization protocol
Number of subjects: 30
Study 7580021 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of hMG (75 IU/day) in flare-up protocol
Number of subjects: 30
Study 7580021 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization protocol (group II)
Number of subjects: 30
Study 7580021 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare-up protocol (group II)
Number of subjects: 30
Study 7580021 — intervention group
Group type: COMPARATOR
Intervention: Desensitization protocol (groups I and II)
Number of subjects: 30
Study 2401707 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8
Study 2401707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 6989227 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmeasured diet with the single restriction of simple sugars
Number of subjects: 30
Study 6989227 — intervention group
Group type: COMPARATOR
Intervention: Exchange type American Diabetes Association diet (caloric defined)
Number of subjects: 30
Study 29777354 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy using a head‐mounted display
Number of subjects: 0
Study 29777354 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 0
Study 27036360 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (40mcg/day per nostril) intranasal spray for 6 months, starting at postoperative week 3 after wound healing
Number of subjects: 70
Study 27036360 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline spray
Number of subjects: 70
Study 25539418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobori drug-eluting stent
Number of subjects: 363
Study 25539418 — intervention group
Group type: COMPARATOR
Intervention: TAXUS drug-eluting stent
Number of subjects: 363
Study 23809343 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy (given prophylactically or in established RDS)
Number of subjects: 0
Study 21084673 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelflow method (arterial cannulation)
Number of subjects: 9
Study 21084673 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelflow method (Finometer)
Number of subjects: 9
Study 21084673 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution
Number of subjects: 9
Study 19242626 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 23
Study 19242626 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 23
Study 19242626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 23
Study 16567857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered human dermal substitute
Number of subjects: 245
Study 16567857 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 245
Study 12663596 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 69
Study 12663596 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 69
Study 10830075 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 2.5%
Number of subjects: 50
Study 10830075 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane 0.5%
Number of subjects: 50
Study 10830075 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (15 ml ropivacaine 7.5 mg/ml with fentanyl 100 micrograms)
Number of subjects: 50
Study 8924951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 0
Study 8924951 — intervention group
Group type: COMPARATOR
Intervention: In vivo mature oocytes
Number of subjects: 0
Study 2004920 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 4 U/ml in 0.9% sodium chloride
Number of subjects: 30
Study 2004920 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (NSS)
Number of subjects: 30
Study 6192514 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic prophylaxis with dextran 70
Number of subjects: 207
Study 6192514 — intervention group
Group type: COMPARATOR
Intervention: Low dose heparin combined with dihydroergotamine
Number of subjects: 207
Study 30415637 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n-3 fatty acids (1 g per day)
Number of subjects: 25871
Study 30246755 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser MTA pulpotomy
Number of subjects: 40
Study 30246755 — intervention group
Group type: COMPARATOR
Intervention: Diode laser ZOE pulpotomy
Number of subjects: 40
Study 26291629 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone and in‐person cognitive‐behavioral therapy
Number of subjects: 100
Study 26291629 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised PHQ‐9
Number of subjects: 100
Study 26291629 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Symptom Checklist‐20
Number of subjects: 100
Study 26291629 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Hamilton Depression Rating Scale
Number of subjects: 100
Study 24064511 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg IC43 with adjuvant
Number of subjects: 163
Study 24064511 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg IC43 with adjuvant
Number of subjects: 163
Study 24064511 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg IC43 with adjuvant
Number of subjects: 163
Study 24064511 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg IC43 without adjuvant
Number of subjects: 163
Study 24064511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 163
Study 22511052 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy containing doxycycline (Group A): esomeprazole 20 mg, bismuth potassium citrate 220 mg, amoxicillin 1 g, doxycycline 100 mg, all bid for ten days.
Number of subjects: 85
Study 22511052 — intervention group
Group type: COMPARATOR
Intervention: Routine quadruple therapy (Group B): esomeprazole 20 mg bid, bismuth potassium citrate 220 mg bid, metronidazole 400 mg bid, tetracycline 750 mg q.6h, for ten days.
Number of subjects: 85
Study 20723635 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboaspiration with a manual device (Export Medtronic)
Number of subjects: 175
Study 20723635 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 175
Study 18436318 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 0
Study 18436318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15669615 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance and chromatic contrast matching functions (CMFs) for younger subjects
Number of subjects: 2
Study 15669615 — intervention group
Group type: COMPARATOR
Intervention: Luminance and chromatic contrast matching functions (CMFs) for older subjects
Number of subjects: 2
Study 12529345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy immediately following surgery
Number of subjects: 477
Study 12529345 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy until clinically indicated
Number of subjects: 477
Study 10374092 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue treatment (3 cycles prior to surgery)
Number of subjects: 60
Study 10374092 — intervention group
Group type: COMPARATOR
Intervention: No preoperative treatment
Number of subjects: 60
Study 8597266 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting corticosteroid
Number of subjects: 12
Study 8597266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-acting corticosteroid
Number of subjects: 12
Study 1423177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg orally daily for 2 years
Number of subjects: 967
Study 1423177 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK 3 g orally daily for 2 years
Number of subjects: 967
Study 1423177 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy with mitomycin C (MMC) and ftorafur (FT)
Number of subjects: 967
Study 1423177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 967
Study 6431470 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.7 to 1.0 micrograms/kg/min, total dose 8.8‐13.2 mg)
Number of subjects: 8
Study 6431470 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (2 mg intramuscularly before sleep onset)
Number of subjects: 8
Study 30612807 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Depression Awareness Program (ADAP)
Number of subjects: 6679
Study 30612807 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 6679
Study 28478693 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing + range of motion exercises
Number of subjects: 90
Study 28478693 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercises
Number of subjects: 90
Study 28478693 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical treatment)
Number of subjects: 90
Study 27176615 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (10 Hz stimulation over left dorsolateral prefrontal cortex)
Number of subjects: 8
Study 27176615 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 8
Study 27176615 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study 25052698 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin at a maximum-tolerated dose (MTD) of 16 mg/m² IV on day 1, combined with high-dose methotrexate (3 g/m² IV), vindesine (3 mg/m² IV), and prednisolone (60 mg/m² IV/orally) on days 1-5.
Number of subjects: 35
Study 23082381 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol‐free essential oils containing mouthrinse (Listerine Zero)
Number of subjects: 92
Study 23082381 — intervention group
Group type: COMPARATOR
Intervention: 5% hydroalcohol negative control rinse
Number of subjects: 92
Study 20719450 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary extract plus vitamin E and omega-3 PUFAs added to standard diet
Number of subjects: 0
Study 20719450 — intervention group
Group type: COMPARATOR
Intervention: Standard diet without rosemary extract, vitamin E, and omega-3 PUFAs
Number of subjects: 0
Study 18757472 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial microincision cataract surgery (B‐MICS)
Number of subjects: 30
Study 18757472 — intervention group
Group type: COMPARATOR
Intervention: Coaxial small‐incision cataract surgery (C‐SICS)
Number of subjects: 30
Study 15627809 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release caffeine (SRC) 300 mg twice a day
Number of subjects: 16
Study 15627809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12435461 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lidocaine (2mg/kg bolus for 5 min followed by 2mg/kg/h infusion for 40 min)
Number of subjects: 16
Study 12435461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative doses of systemic lidocaine (0.5-2mg/kg) injected 30 min after incision
Number of subjects: 16
Study 10491676 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNW plan
Number of subjects: 251
Study 10491676 — intervention group
Group type: COMPARATOR
Intervention: Usual-care diet
Number of subjects: 251
Study 8086649 — intervention group
Group type: EXPERIMENTAL
Intervention: Health test and health conversations in general practice
Number of subjects: 898
Study 8086649 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 898
Study 2456626 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 36
Study 2456626 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 36
Study 29735963 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus hydrotherapy
Number of subjects: 126
Study 29735963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 27955807 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRGF)
Number of subjects: 58
Study 27955807 — intervention group
Group type: COMPARATOR
Intervention: Standard cure with saline (Control)
Number of subjects: 58
Study 25043647 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (a nitric oxide donor) given for seven days
Number of subjects: 4011
Study 25043647 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing pre-stroke antihypertensive therapy
Number of subjects: 4011
Study 25043647 — intervention group
Group type: COMPARATOR
Intervention: No glyceryl trinitrate
Number of subjects: 4011
Study 25043647 — intervention group
Group type: COMPARATOR
Intervention: Stopping (temporarily for seven days) pre-stroke antihypertensive drugs
Number of subjects: 4011
Study 23116438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemex Rx bone cement
Number of subjects: 44
Study 23116438 — intervention group
Group type: COMPARATOR
Intervention: Palacos R bone cement
Number of subjects: 44
Study 20044997 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 157
Study 20044997 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogalvanic stimulation (EGS)
Number of subjects: 157
Study 20044997 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 157
Study 20044997 — intervention group
Group type: COMPARATOR
Intervention: Control group (possible LAS)
Number of subjects: 157
Study 18485457 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam
Number of subjects: 60
Study 18485457 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg lornoxicam
Number of subjects: 60
Study 18485457 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 60
Study 16401155 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose divalproex
Number of subjects: 71
Study 16401155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose divalproex
Number of subjects: 71
Study 12771535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialyzers (e.g. cellulose triacetate, polymethylmethacrylate) or hemodiafiltration
Number of subjects: 125
Study 12771535 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialyzers (polysulfone or cellulose triacetate membranes)
Number of subjects: 125
Study 10232740 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT recipients
Number of subjects: 54
Study 10232740 — intervention group
Group type: EXPERIMENTAL
Intervention: Histocompatible BMT recipients
Number of subjects: 54
Study 10232740 — intervention group
Group type: COMPARATOR
Intervention: Unrelated BMT recipients
Number of subjects: 54
Study 10232740 — intervention group
Group type: COMPARATOR
Intervention: Histocompatible BMT recipients >3 years post-BMT
Number of subjects: 54
Study 8610383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 800 mg q 8 hr for at least 24 h
Number of subjects: 46
Study 8610383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8610383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF)
Number of subjects: 46
Study 1467165 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CIV) of morphine
Number of subjects: 66
Study 1467165 — intervention group
Group type: COMPARATOR
Intervention: Intermittent parenteral opioids (IPO)
Number of subjects: 66
Study 1467165 — intervention group
Group type: COMPARATOR
Intervention: Oxygen inhalation (50% O2)
Number of subjects: 66
Study 6369238 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital treatment (two loading doses of 10 mg/kg 12 hours apart, followed by a maintenance dose of 2.5 mg/kg every 12 hours for 6 days)
Number of subjects: 42
Study 6369238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 31655812 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5734
Study 31655812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5734
Study 29765213 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once-daily add-on therapy
Number of subjects: 3274
Study 27281722 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine
Number of subjects: 99
Study 27281722 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 99
Study 27281722 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 99
Study 27281722 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 99
Study 24322216 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected position
Number of subjects: 20
Study 24322216 — intervention group
Group type: COMPARATOR
Intervention: Other positions (including crucifix-type position)
Number of subjects: 20
Study 22249013 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 66
Study 22249013 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 66
Study 22249013 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CA)
Number of subjects: 66
Study 20228999 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol continuous infusion (0.8 mg/kg induction dose and 3 mg/kg/h maintenance dose)
Number of subjects: 60
Study 20228999 — intervention group
Group type: COMPARATOR
Intervention: Intermittent midazolam injection (mean total dose 10.3 +/- 4.5 mg)
Number of subjects: 60
Study 17410104 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide and fludrocortisone
Number of subjects: 21
Study 17410104 — intervention group
Group type: COMPARATOR
Intervention: Ammonium chloride
Number of subjects: 21
Study 15602505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose liquid fluoxetine (mean final dose: 9.9±4.35 mg/day)
Number of subjects: 45
Study 15602505 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid fluoxetine
Number of subjects: 45
Study 11943041 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg power
Number of subjects: 45
Study 11943041 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg strength
Number of subjects: 45
Study 10194869 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 10194869 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 0
Study 7598779 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic hydrogel with polyurethane secondary dressing
Number of subjects: 0
Study 7598779 — intervention group
Group type: COMPARATOR
Intervention: Saline moistened gauze (wet-to-dry technique)
Number of subjects: 0
Study 2030849 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of both the visceral and parietal peritoneum with absorbable suture (N = 59)
Number of subjects: 113
Study 2030849 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal closure (N = 54)
Number of subjects: 113
Study 6760183 — intervention group
Group type: EXPERIMENTAL
Intervention: VCAD protocol
Number of subjects: 10
Study 6760183 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP protocol
Number of subjects: 10
Study 31141288 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow loaded breathing training (SLB): 25% maximum inspiratory pressure, 6 breaths per minute, 60 breaths every day for 8 weeks
Number of subjects: 20
Study 31141288 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow loaded breathing training (SLB)
Number of subjects: 20
Study 31141288 — intervention group
Group type: COMPARATOR
Intervention: Deep breathing control (CON)
Number of subjects: 20
Study 27502323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) guided by the 15-gene expression signature
Number of subjects: 0
Study 27502323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) guided by clinical stage
Number of subjects: 0
Study 27502323 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 0
Study 27502323 — intervention group
Group type: COMPARATOR
Intervention: Use of the 15-gene expression signature
Number of subjects: 0
Study 25727713 — intervention group
Group type: EXPERIMENTAL
Intervention: 2- to 5-day PLTs
Number of subjects: 122
Study 25727713 — intervention group
Group type: COMPARATOR
Intervention: 6- or 7-day PLTs
Number of subjects: 122
Study 24502891 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous blood sampling in women with PCOS
Number of subjects: 129
Study 24502891 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous blood sampling in women with IGT at baseline (n = 6)
Number of subjects: 129
Study 24502891 — intervention group
Group type: COMPARATOR
Intervention: Peripheral venous blood sampling in healthy controls
Number of subjects: 129
Study 24502891 — intervention group
Group type: COMPARATOR
Intervention: Peripheral venous blood sampling in healthy controls with IGT at baseline (n = 3)
Number of subjects: 129
Study 22519750 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-specific communication
Number of subjects: 1478
Study 22519750 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental smoking
Number of subjects: 1478